Relation Therapeutics is a Biotech company based in London, United Kingdom. It has raised $80M in total funding. Latest round: Seed.
Relation Therapeutics funding overview
Relation Therapeutics is a Biotech company based in London, United Kingdom. Relation Therapeutics has raised $80M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Seed announced in March 2024. The round record for Relation Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include DCVC, NVentures, Khosla Ventures, OMERS Ventures, firstminute Capital, Magnetic Ventures. 6 distinct backers are named across the disclosed rounds.
Relation Therapeutics at a glance
Total raised
$80M
Latest round
Seed
Latest round date
March 2024
Industry
Biotech
Headquarters
London, United Kingdom
Notable investors
DCVC, NVentures, Khosla Ventures, OMERS Ventures, firstminute Capital, Magnetic Ventures
Frequently asked about Relation Therapeutics funding
How much has Relation Therapeutics raised?
Relation Therapeutics has raised $80M in total disclosed funding across the rounds on record.
Who has invested in Relation Therapeutics?
DCVC, NVentures, Khosla Ventures, OMERS Ventures, firstminute Capital, Magnetic Ventures are named among the investors backing Relation Therapeutics.
What was the latest Relation Therapeutics funding round?
The most recent disclosed round is a Seed, announced in March 2024.
Where is Relation Therapeutics based?
Relation Therapeutics is based in London, United Kingdom.
What sector does Relation Therapeutics operate in?
Relation Therapeutics is tracked under Biotech from London, United Kingdom, with $80M in disclosed funding.
When did Relation Therapeutics last raise?
The last disclosed Relation Therapeutics round closed in March 2024 at Seed.
Every Relation Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in London at a similar stage.
